Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7239-7245

  Akinwande, Olaguoke ^a   Miller, Amanda ^b   Hayes, David ^c   O'hara, Ryan ^d   Tomalty, Dana ^e   Martin, Robert C G ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c Baptist Health Arkansas   (United States)

^d PC   (United States)

^e HUNTSVILLE HOSPITAL   (United States)

Author keywords

Capecitabine; Chemoembolization; Drugeluting beads; Irinotecan; Toxicity

Indexed keywords

CAPECITABINE; HEME; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG CARRIER; FLUOROURACIL; MICROSPHERE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHOLECYSTITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG FATALITY; EVENING DOSAGE; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; INFECTION; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; POST EMBOLIZATION SYNDROME; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; INTRAARTERIAL DRUG ADMINISTRATION; LIVER; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG CARRIERS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED;

EID: 84918588703     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Allen-Mersh TG, Earlam S, Fordy C, Abrams K and Houghton J: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260, 1994.
2. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F and Saltz L: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012, 2008.
3. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C and de Gramont A: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 5727-5733, 2009.
4. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759, 2007.
5. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J and Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93: 510-514, 2005.
6. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 498-504, 1984.
7. Daniels JR, Sternlicht M and Daniels AM: Collagen chemoembolization: pharmacokinetics and tissue tolerance of cis-diamminedichloroplatinum(II) in porcine liver and rabbit kidney. Cancer Res 48: 2446-2450, 1988.
8. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
10. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V and Coschiera P: Intra-arterial infusion of irinotecanloaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32: 1387-1395, 2012.
11. Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D and Abbruzzese JL: Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22: 2078-2083, 2004.
12. Hofheinz RD, Hartmann JT, Willer A, Oechsle K, Hartung G, Gnad U, Saussele S, Kreil S, Bokemeyer C, Hehlmann R and Hochhaus A: Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer 91: 834-838, 2004.
13. Lee JJ, Kim TM, Yu SJ, Kim DW, Joh YH, Oh DY, Kwon JH, Kim TY, Heo DS, Bang YJ and Kim NK: Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Jpn J Clin Oncol 34: 400-404, 2004.
14. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK and Park K: Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56: 10-14, 2005.
15. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J and Gores GJ: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711, 2008.
16. Martin RC 2nd, Scoggins CR, Tomalty D, Schreeder M, Metzger T, Tatum C and Sharma V: Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 16: 1531-1538, 2012.
17. Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM and Tatum C: Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 33: 960-966, 2010.
18. Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, Padr R, Rocek M, Scupchenko A and Tatum C: Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18: 192-198, 2011.
19. Martin RC, Joshi J, Robbins K, Tomalty D, OHara R and Tatum C: Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan (DEBIRI): Multi-Institutional Registry. J Oncology 2009: 539795, 2009.
20. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W and Schmoll HJ: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223, 2007.
21. Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J and Shellito P: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 91: 839-843, 2004.
22. Richardson AJ, Laurence JM and Lam VW: Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol 24: 1209-1217, 2013.
23. Saif MW, Kaley K, Brennan M, Garcon MC and Rodriguez G: Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. Anticancer Res 33: 2743-2746, 2013.
24. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
25. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J and Scheithauer W: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704, 2005.